


The analysis indicates that economies with high public debt in the Americas respond nearly three times more significantly in terms of national risk premium when fiscal deficits increase compared to those with lower debt. The rise in risk premium is...
AIxC robotics becomes the new business focus: AIxC Holdings plans to gradually exit its digital asset reserve strategy and direct resources towards developing commercial services in the robotics sector. AIxC Holdings, traded on Nasdaq under the ticker AIXC, is restructuring its business around robot...
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.